Beyond Paxlovid: The Urgent Need for Better Meds
Beyond Paxlovid: The Urgent Need for Better Meds
Beyond Paxlovid: The Urgent Need for Better Meds
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
Access Metformin to reduce risk of Long COVID
A clinical trial showed metformin reduced risk of #LongCovid by ~41% when taken during acute #covid! Access #metformin (covid study dosing) easier here: